Shares of Guardant Health (NASDAQ:GH) jumped 12% in early trading Tuesday on news that Medicare coverage for its Guardant Reveal blood test has been expanded to include monitoring for disease ...

Guardant and Pfizer will use liquid biopsy tests in global oncology clinical trials, including monitoring ctDNA as a therapy response marker Pfizer gains access to Guardant’s testing ...

The latest price target for Guardant Health (NASDAQ:GH) was reported by Piper Sandler on May 6, 2025. The analyst firm set a price target for $60.00 expecting GH to rise to within 12 months (a ...

Diagnostics company Guardant Health (NASDAQ:GH) will be reporting earnings tomorrow after market hours. Here’s what you need to know. Guardant Health beat analysts’ revenue expectations by 4.8 ...

In addition, we were excited to share strong data for Shield multi-cancer in partnership with the National Cancer Institute, which we believe establishes Guardant as a leader in the field of multi ...

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced a strategic collaboration with Pfizer, Inc. (NYSE: PFE), to support ...

--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, presented data today from a study showing that its methylation-based Shield™ multi-cancer detection ...

Guardant Health (GH) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended March 2025. This widely-known consensus outlook ...